Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects 18 years of age or older~* Subjects with a diagnosis of Adult-onset Rheumatoid Arthritis of at least 3 months as defined by the 1987 American College of Rheumatology (ACR) classification criteria~* Subjects with active Rheumatoid Arthritis as defined by:~  * 4 tender joints (28 joint count) at Screening and Baseline Visits; and~ * 4 swollen joints (28 joint count) at Screening and Baseline Visits~* Subjects who have had an unsatisfactory response or intolerance to at least 1 traditional Disease-modifying Antirheumatic Drugs (DMARD)~Exclusion Criteria:~* Subjects must not have a diagnosis of any other inflammatory Arthritis~* Subjects must not have greater than 3 Arthroplasties due to Rheumatoid Arthritis and/or Steinbrocker IV Functional Capacity~* Subjects must not have a secondary non-inflammatory type of Arthritis that would interfere with study evaluation~* Subjects must not be diagnosed with Fibromyalgia with sufficient symptoms requiring treatment~* Subjects must not have a history of Infected Joint Prosthesis~* Subjects must not have discontinued biological therapy for their Rheumatoid Arthritis due to Severe Hypersensitivity Reaction or Anaphylactic Reaction~* Subjects must not have received more than 2 anti- Tumor Necrosis Factor (TNF) agents prior to enrollment~* Subjects must not have received treatment with Abatacept and/or Rituximab or have received any experimental or approved B cell therapeutic agent~* Subjects must not have a history of chronic alcohol or drug abuse~* Subjects must not have known hypersensitivity to any components of the investigational medicinal product~* Subjects must not have a history of chronic infections, recent serious or life-threatening infection within 6 months or any current sign or symptom that may indicate an infection~* Subjects must not have a history of a Blood Dyscrasias~* Subjects with known Tuberculosis (TB) Disease, high risk of acquiring TB or latent TB infection~* Subjects must not be at high risk of infection~* Subjects must not have a history of Lymphoproliferative Disorder including Lymphoma signs and symptoms suggestive of Lymphoproliferative Disease~* Subjects must not have concurrent acute or chronic Viral Hepatitis B or C~* Subjects must not have known Human Immunodeficiency Virus (HIV) infection~* Subject must not have concurrent Malignancy or history of Malignancy~* Subjects must not have a current or recent history of severe, progressive, and/or uncontrolled Renal, Hepatic, Hematological, Gastrointestinal, Endocrine, Pulmonary, Cardiac, Neurological or Cerebral Disease~* Subjects must not have Class III or IV Congestive Heart Failure~* Subjects must not have history of, or suspected Demyelinating Disease of the Central Nervous System~* Subjects must not have a history of adverse reaction to Polyethylene Glycol (PEG)~* Subjects must not have significant laboratory abnormalities which in the investigators judgment would make the subject unsuitable for inclusion~* Subjects must not have a known history or clinically active infection with Histoplasma, Coccidiodes, Paracoccidioides, Pneumocystis, Nontuberculous Mycobacteria, Blastomyces or Aspergillus~* Subject must not have a known history of or be currently diagnosed with Systemic Lupus Erythematosus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAPID3 to assess response to Cimzia (Type: OTHER): RAPID3 is a subject-based assessment tool used to assess subject's response to Cimzia.~Subjects will be randomized to a patient measure tool, a tool based on patient-report outcomes (RAPID3); using a total score of 30 points
- CDAI to assess response to Cimzia (Type: OTHER): CDAI is an investigator-based assessment tool used to assess subject's response to Cimzia.~Subjects will be randomized to a clinical measures tool, a tool based on Investigator measures without the need for a lab value (CDAI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete